危重症患者β-内酰胺类抗生素与环丙沙星模型引导精准给药:多中心随机临床试验
该多中心随机对照试验在荷兰8家医院纳入ICU接受抗生素治疗的患者,比较基于治疗药物监测联合药代动力学建模的模型引导精准给药(MIPD)与标准给药。共分析388例(MIPD组189例,标准给药组199例),中位年龄64岁(IQR 55-71)。主要终点ICU住院时间无显著差异(MIPD组10天 vs 标准给药组8天;IRR=1.16;95%CI 0.96-1.41;p=0.13),第1天和第3天目标达成率亦无显著差异(第1天55.6% vs 60.9%,p=0.24;第3天59.5% vs 60.4%,p=0.84),其他次要结局无显著差异。作者认为未能显示MIPD对ICU住院时间的获益,并指出需要寻找其他剂量优化方法。
要点
- 在ICU抗生素治疗患者中,MIPD组与标准给药组ICU住院时间无显著差异:MIPD组10天 vs 标准给药组8天(IRR=1.16;95%CI 0.96-1.41;p=0.13)。
- 第1天目标达成率MIPD组55.6% vs 标准给药组60.9%(p=0.24),第3天59.5% vs 60.4%(p=0.84),均无显著差异。
- ICU死亡率、医院死亡率、28天死亡率、6个月死亡率、SOFA评分变化、不良事件等次要结局均无显著差异。
- 作者结论:未能显示β-内酰胺类抗生素与环丙沙星MIPD对危重症患者ICU住院时间的获益,需寻找其他剂量优化方法。
适用人群与场景
- 纳入重症监护病房(ICU)接受抗生素治疗的患者,来自荷兰8家医院。
处置流程与药物剂量
- MIPD组:根据治疗药物监测(血清药物水平监测)联合β-内酰胺类抗生素与环丙沙星的药代动力学建模,调整剂量和给药间隔。
- 标准给药组:按标准剂量给药。
研究设计与关键结果
- 研究类型:多中心随机对照试验,在荷兰8家医院开展,共分析388例患者(MIPD组189例,标准给药组199例),中位年龄64岁(IQR 55-71)。
- 主要终点:ICU住院时间,MIPD组10天 vs 标准给药组8天(IRR=1.16;95%CI 0.96-1.41;p=0.13),无显著差异。
- 目标达成率:第1天(T1)MIPD组55.6% vs 标准给药组60.9%(p=0.24);第3天(T3)MIPD组59.5% vs 标准给药组60.4%(p=0.84),均无显著差异。
- 次要结局:ICU死亡率、医院死亡率、28天死亡率、6个月死亡率、SOFA评分变化(delta SOFA)、不良事件均无显著差异。
证据类型、等级与局限
- 证据类型:多中心随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:未能显示β-内酰胺类抗生素与环丙沙星MIPD对危重症患者ICU住院时间的获益;作者认为数据提示需要寻找其他剂量优化方法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Individualising drug dosing using model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin has been proposed as an alternative to standard dosing to optimise antibiotic efficacy in critically ill patients. However, randomised clinical trials (RCT) on clinical outcomes have been lacking.
METHODS: This multicentre RCT, including patients admitted to the intensive care unit (ICU) who were treated with antibiotics, was conducted in eight hospitals in the Netherlands. Patients were randomised to MIPD with dose and interval adjustments based on monitoring serum drug levels (therapeutic drug monitoring) combined with pharmacometric modelling of beta-lactam antibiotics and ciprofloxacin. The primary outcome was ICU length of stay (LOS). Secondary outcomes were ICU mortality, hospital mortality, 28-day mortality, 6-month mortality, delta sequential organ failure assessment (SOFA) score, adverse events and target attainment.
RESULTS: In total, 388 (MIPD n = 189; standard dosing n = 199) patients were analysed (median age 64 [IQR 55-71]). We found no significant differences in ICU LOS between MIPD compared to standard dosing (10 MIPD vs 8 standard dosing; IRR = 1.16; 95% CI 0.96-1.41; p = 0.13). There was no significant difference in target attainment before intervention at day 1 (T1) (55.6% MIPD vs 60.9% standard dosing; p = 0.24) or at day 3 (T3) (59.5% vs 60.4%; p = 0.84). There were no significant differences in other secondary outcomes.
CONCLUSIONS: We could not show a beneficial effect of MIPD of beta-lactam antibiotics and ciprofloxacin on ICU LOS in critically ill patients. Our data highlight the need to identify other approaches to dose optimisation.
参考来源
- Ewoldt TMJ, Abdulla A, Rietdijk WJR, et al. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. Intensive Care Med. 2022. PMID: 36350354. doi:10.1007/s00134-022-06921-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。